MetabolicFDA Approved

Tirzepatide

Also known as Mounjaro · Zepbound

Dual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.

Overview

Tirzepatide is a 39-amino-acid synthetic peptide acting as a dual agonist at GIP and GLP-1 receptors. Approved by the FDA for type 2 diabetes (2022) and chronic weight management (2023).

Mechanism

Co-activation of GIP + GLP-1 receptors; complementary insulinotropic and satiety effects.

Research areas

Type 2 diabetes
Obesity
Obstructive sleep apnea

Related peptides

Semaglutide

Long-acting GLP-1 receptor agonist for glycemic control and weight management.

View

Retatrutide

Investigational triple agonist (GIP / GLP-1 / glucagon) in late-stage trials.

View

Cagrilintide

Long-acting amylin analog studied alongside semaglutide as CagriSema.

View